Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

The Biosimilar Void

Articles

Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined. 

Trump Says Pharma Industry Should Expect Tariffs by Aug. 1

In the third part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, recommends regulatory or verification mechanisms that can help safely legitimize online medicine procurement.

Cracking Down on Illegal Online Pharmacies

Pharma Pulse 7/17/25: Inside the GLP-1 Strategy Driving Competitive Edge in Obesity Clinical Research; Eisai Highlights Long-Term Efficacy of Lenvima in Advanced HCC Treatment

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.

Thermo Fisher, Sanofi Expand Partnership to Boost Sterile Drug Production

In the second part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, explains how the private sector should strategically support and scale efforts to ensure that HCPs globally receive substandard and falsified medicine detection training. 

Creating a Unified Strategy to Advance Education on Counterfeit Medicines

Executive Vice President at Founder Shield.


Why startups and life sciences companies should approach this booming sector with extreme caution.

The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet

Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

Designing Effective Value-Based Contracts: Timing, Evidence, and Risk Alignment

In the third part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, explains the strategies that manufacturers should adopt to balance investment in innovation with lifecycle management.

Balancing Innovation and Lifecycle Strategy in the Era of the IRA 

Pharma Pulse 7/16/25: LEAP-002 Study Shows Five Year Survival Consistency in Unresectable Liver Cancer; Building Clinical Trial Infrastructure Inside Pharmacies

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs